← All trials
NCT05359419
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 15, 2022
- Primary completion
- Aug 30, 2023
- Completion date
- Dec 30, 2023
- First posted
- May 3, 2022
- Last posted
- May 4, 2022
- Enrollment
- 20
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Goldman, Butterwick, Fitzpatrick and GroffLead sponsor
- Biofrontera Bioscience GmbHCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.